skip to content
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Good morning, I am looking for an alternative to big American tech. Hopefully in Europe or perhaps Asia. When large Canadian pension plans are moving away from US investments, I think this is worth exploring. Would appreciate your thoughts.
Read Answer Asked by Joanne on April 17, 2025
Q: Would you recommend to buy, hold, or sell GSK?

I ask on behalf of a relative I help with investing. GSK is currently 1.3% of their portfolio. I had already been thinking of recommending that they sell when the news on June 3 came out:

"Shares of GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker."

They are at a 15% loss with their GSK holding (less if you consider dividends), but luckily it is a small part of the portfolio.

I am leaning toward a 'sell recommendation' but am open to counter arguments.

Thanks so much!
Read Answer Asked by Robert on June 18, 2024
Insiders
Share Information
SEC Filings
News and Media